FDA Grants Calliditas Accelerated Approval Of Tarpeyo To Reduce Proteinuria In IgA Nephropathy
16/12 04:13
(RTTNews) - The U.S. Food and Drug Administration has approved Tarpeyo or budesonide delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy or IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPC...